Table 2 PAH-targeted therapy received prior to switching to riociguat
Therapy, n (%) | Full analysis set (n = 300) |
|---|---|
Any prior therapy | 84 (28) |
Endothelin receptor antagonists | 44 (15) |
Ambrisentan | 8 (3) |
Bosentan | 36 (12) |
PDE5 inhibitors | 58 (19) |
Sildenafil | 42 (14) |
Tadalafil | 16 (5) |
Prostacyclins and prostacyclin analogues | 7 (2) |
Beraprost | 1 (<1) |
Iloprost | 6 (2) |
Combination therapy | 24 (8) |
Double therapy | 23 (8) |
Triple therapy | 1 (<1) |